1. Expression of rotavirus capsid protein, VP6, in various yeasts
- Author
-
Rakaki, Matshepo Elizabeth, O’Neill, Hester G., Albertyn, Jacobus, Rakaki, Matshepo Elizabeth, O’Neill, Hester G., and Albertyn, Jacobus
- Abstract
Rotavirus infection is one of the six leading causes of death among children under the age of five years. Globally it causes more than 215 000 deaths annually of which 65% occur in low- and/or middle-income countries. The two licenced live-attenuated vaccines (Rotarix™ and RotaTeq™) tend to have a lower efficacy in low- and/or middle-income countries. The lower efficacy of rotavirus live-attenuated vaccines could be due to maternal antibodies and oral polio vaccines interfering with rotavirus vaccine uptake. Rotavirus live-attenuated vaccines have been associated with reassortment with circulating genotype strains. As alternative, subunit vaccines such as viral proteins can be considered. Rotavirus VP6 protein is considered as a candidate for subunit vaccine development. Rotavirus VP6 antibodies are responsible for long lasting immunity and the antibodies against VP6 block the release of the viral mRNA. Previous studies showed rotavirus VP6 provide heterologous protection by a significant reduction of virus shedding in mice and gnotobiotic pigs. Various recombinant yeasts were engineered by a previous MSc student, Mr M.S. Makatsa, using a unique yeast expression vector (pKM177). The recombinant yeasts contained an open reading frame (ORF) encoding rotavirus VP6 for the RVA/Human wt/ZAF/GR10924/1999/G9P[6] strain. The ORF was codon optimised to favour expression in Arxula adeninivorans (AO), Kluyveromyces lactis (KO) and Pichia pastoris/Pichia angusta (PO). However, there was no expression of VP6 optimised for expression in A. adeninivorans and K. lactis due to an additional out-of-frame ATG in the promoter region of the expression vector. In this study, the additional ATG was successfully removed by site-directed mutagenesis and the Kozak sequence was optimised to produce modified delATG_pKM177_AOVP6 and delATG_pKM177_KOVP6 constructs. The modified delATG_pKM177_AOVP6, delATG_pKM177_KOVP6 as well as delATG_pKM177_POVP6, the modified plasmid containing the VP6 ORF co, National Research Foundation (NRF), PRF
- Published
- 2018